ARTIVION, INC. (AORT) Stock
AORT has an Alpha Score of 22 out of 100 (poor), computed on Nov 5, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 5 trades in AORT since 2023: 3 purchases and 2 sales, most recently Gilbert Cisneros (purchase, Aug 20, 2026). 3 of the hedge funds AlphaScala tracks reported AORT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $18.60M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 5, 2026. Its trailing P/E ratio is 118.3 and its net margin -0.7% (key statistics as of Nov 5, 2026).
What is AORT's Alpha Score?
How it works →Alpha Score of 22 reflects poor overall profile with weak momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded ARTIVION, INC. (AORT)?
Most recent: Gilbert Cisneros (purchase, Aug 20, 2026); records start Jun 13, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-08-20 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-07-16 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-10-09 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-07-14 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-06-13 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all AORT political trades →Which hedge funds own AORT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 828K | $18.60M | +1068% |
| D.E. Shaw David Shaw | 438K | $9.85M | +6615% |
| Renaissance Technologies Jim Simons (founder) | 68K | $1.52M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ARTIVION, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Green Andrew M | SVP, Regulatory and Quality | SELL | 11.5K | $287K |
| Sep 3, 26 | Green Andrew M | SVP, Regulatory and Quality | SELL | 1.5K | $39K |
| Sep 2, 26 | Green Andrew M | SVP, Regulatory and Quality | SELL | 6.5K | $177K |
| Aug 19, 26 | Mackin James P | President & CEO | SELL | 70.0K | $2.0M |
| Aug 14, 26 | Berry Lance A | EVP, COO, CFO & Treasurer | SELL | 715 | $20K |
| Aug 14, 26 | Green Andrew M | SVP, Regulatory and Quality | SELL | 616 | $18K |
| Aug 12, 26 | Holloway Jean F | SVP, General Counsel | SELL | 977 | $28K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are AORT's key statistics?
Key statistics as of Nov 5, 2026
How does AORT's valuation compare with the Healthcare sector?
| Metric | AORT | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 118.3 | 28.7 | 108 |
| Net margin | -0.67% | 4.11% | 160 |
| Return on equity | -0.71% | 5.18% | 180 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
AORT price chart
Powered by TradingViewWhat does ARTIVION, INC. do?
Artivion Inc. is a medical device company focused on providing innovative technology solutions aimed at improving patient outcomes. Its primary function is to develop, manufacture, and sell devices associated with cardiac and vascular surgery, with a particular emphasis on cryopreservation and heart valve structures. The company's product portfolio serves critical areas such as aortic repair, heart valve therapy, and advanced cryogenic preservation techniques, underpinning its vital presence in the cardiovascular treatment sector. Its products are essential in supporting cardiac surgeons and healthcare professionals in utilizing life-saving technologies during complex medical procedures. Artivion Inc. serves a global market, impacting numerous aspects of healthcare by enabling the treatment of complex heart conditions and elevating surgical efficiency and efficacy. Headquartered in the United States, the company continues its commitment to innovation and quality in medical technology, playing a crucial role in advancing health outcomes and directly contributing to the fields of cardiovascular surgery and transplant medicine.